ABLATE Post -Appro val Study  
AtriCure Inc. 
Page 1 of 46  CONFIDENTIAL  
Rev. M   
  
 
 
 
ABLATE POST APPROVAL STUDY  
 
ATRICURE SYNERGY ABLATION LESIONS FOR NON -PAROXYSMAL FORMS OF 
ATRIAL FIBRILLATION TREATMENT DURING CONCOMITANT ON -PUMP 
ENDO/EPICARDIAL CARDIAC SURGERY  
 
Protocol  Number:  CP2011 -1 
 
Sponsor:  AtriCure,  Inc. 
6217 Centre Park Drive  
West Chester, OH 45069  
 
Shana Zink, Vice President Clinical Affairs  
Email: szink@atricure.com  
 
Data  Management,  Boston Biomedical  Associates  
Statistics  and Safety  386 West Main Street – Suite  7 
Northborough, Massachusetts 01532  
 
PAS Steering  Committee  Patrick McCarthy, MD – Chairperson  
 
 
Study  Centers:  To be maintained in study  files 
Core  Lab:  Agility Centralized Research Services,  Inc. 
A CardioNet Company  
2275 Half Day Road Suite # 133 
Bannockburn, IL 60015  
 
Issue  Date/Version:  11 April 2014 / Version  L 
 
Amendment Date /Version:  23 June 2014 / Version M  
 
Confidential Material:  
This document is the property of AtriCure, Inc. and is confidential and proprietary. The 
information contained herein is believed to be accurate and complete as of the date of 
preparation. The contents of this document may not be reproduced without prior expressed 
consent by AtriCure, Inc.  
ABLATE Post -Appro val Study  
AtriCure Inc. 
Page 2 of 46  CONFIDENTIAL  
Rev. M   
  
 
Protocol Signature Page  
 
 
 
The signature below constitutes the Investigator has reviewed the protocol and the attachments, 
and agrees to provide the necessary assurances that this trial will be conducted according to all 
stipulations of the protocol, including all statements regarding confidentiality, and according to 
local legal and regulatory requirements and applicable regulat ions and ICH/GCP guidelines.  
 
 
 
 
Investigational Site  Name:     
 
 
Investigator Designation (please select as appropriate) :  
 
 Principal  Investigator   Physician  Sub-Investigator   Non -Physician  Sub-Investi  
 
 
Investigator Name  (Print ):    
 
 
Investigator  Signature:    
 
 
Date of Signature  (DD-Month -YYYY ):    
ABLATE Post -Appro val Study  
AtriCure Inc. 
Page 3 of 46  CONFIDENTIAL  
Rev. M   
  
 
TABLE OF CONTENTS  
1.0 INTRODUCTION: BACKGROUND INFORMATION AND  SCIENTIFIC  RATIONALE  ................................ .. 10 
1.1 BACKGROUND  CLINICAL  INFORMATION  ................................ ................................ ................................  10 
2.0 ATRICURE  SYSTEM  ................................ ................................ ................................ ...........................  10 
3.0 ATRICURE SYNERGY ABLATION  SYSTEM  LABELING  ................................ ................................ ..........  11 
3.1 INDICATIONS  FOR USE ................................ ................................ ................................ .......................  11 
3.2 CONTRAINDICATIONS  ................................ ................................ ................................ ........................  11 
3.3 WARNINGS  AND  PRECAUTIONS  ................................ ................................ ................................ ...........  11 
4.0 ATRIAL  FIBRILLATION  CLASSIFICATION  ................................ ................................ ............................  11 
5.0 STUDY  OBJECTIVE  ................................ ................................ ................................ ............................  11 
6.0 STUDY  DESIGN  ................................ ................................ ................................ ................................ . 12 
6.1 SITE SELECTION  ................................ ................................ ................................ ...............................  12 
6.2 STUDY CENTER  INITIATION /START  UP ................................ ................................ ................................ .. 13 
6.3 ENROLLMENT  PROCEDURES  ................................ ................................ ................................ ...............  15 
6.4 INFORMED  CONSENT PROCEDURES  ................................ ................................ ................................ ..... 16 
6.5 PAS TIMELINE  ................................ ................................ ................................ ................................ . 16 
7.0 STUDY  OUTCOMES  ................................ ................................ ................................ ..........................  17 
7.1 PRIMARY  EFFICACY OUTCOME  ................................ ................................ ................................ ............  17 
7.2 SECONDARY  EFFICACY  OUTCOME  ................................ ................................ ................................ ........  17 
7.3 PRIMARY  SAFETY  OUTCOME  ................................ ................................ ................................ ..............  17 
7.4 SECONDARY  SAFETY  OUTCOMES  ................................ ................................ ................................ .........  18 
8.0 DEVICE DESCRIPTION, POTENTIAL RISK BENEFITS &  STUDY  JUSTIFICATION  ................................ ..... 18 
8.1 POTENTIAL RISKS AND  BENEFITS  ................................ ................................ ................................ .........  18 
9.0 ELIGIBILITY  CRITERIA  ................................ ................................ ................................ ........................  19 
9.1 SUBJECT  INCLUSION  CRITERIA  ................................ ................................ ................................ .............  19 
9.2 SUBJECT  EXCLUSION  CRITERIA  ................................ ................................ ................................ ............  19 
10.0  REASONS  FOR  WITHDRAWAL  ................................ ................................ ................................ ..........  19 
11.0  TREATMENT  OF SUBJECTS  ................................ ................................ ................................ ................  20 
12.0 CLINICAL  ASSESSMENTS  ................................ ................................ ................................ ..................  23 
ABLATE Post -Appro val Study  
AtriCure Inc. 
Page 4 of 46  CONFIDENTIAL  
Rev. M   
 12.1 REPEAT ABLATION AND /OR CARDIOVERSION  PROCEDURES  ................................ ................................ ...... 24 
12.2 PERMANENT PACEMAKER  IMPLANTATIONS  (PPM)  ................................ ................................ .................  24 
12.3 STANDARDIZATION OF ANTI-ARRHYTHMIC DRUG USE DURING  FOLLOW -UP PERIOD  ................................ ...... 24 
13.0 ASSESSMENT  OF SAFETY  ................................ ................................ ................................ ..................  25 
13.1 ADVERSE  EVENTS  ................................ ................................ ................................ .............................  25 
13.2 ANTICIPATED  ADVERSE  EVENTS  ................................ ................................ ................................ ..........  25 
13.3 EVENTS THAT DO NOT REQUIRE REPORTING TO  THE SPONSOR  ................................ ................................ .... 26 
13.4 SERIOUS  ADVERSE  EVENTS  ................................ ................................ ................................ .................  27 
14.0  CLINICAL EVENTS  COMMITTEE  (CEC)  ................................ ................................ ................................  27 
15.0 MEDICAL  DEVICE  REPORTING  ................................ ................................ ................................ ..........  28 
15.1 MANUFACTURER  REPORTING  REQUIREMENTS  ................................ ................................ .......................  28 
16.0 STATISTICAL  CONSIDERATIONS  ................................ ................................ ................................ ........  28 
16.1 STATISTICAL  OVERVIEW  ................................ ................................ ................................ .....................  28 
16.2 ANALYSIS  POPULATIONS  ................................ ................................ ................................ ....................  28 
16.3 SAMPLE SIZE CALCULATIONS  AND  ASSUMPTIONS  ................................ ................................ ...................  29 
16.4 SAFETY  ................................ ................................ ................................ ................................ ..........  29 
16.5 EFFICACY  ................................ ................................ ................................ ................................ ........  30 
16.6 STATISTICAL  ANALYSES  ................................ ................................ ................................ ......................  30 
17.0 QUALITY CONTROL AND  QUALITY  ASSURANCE  ................................ ................................ ................  31 
17.1 PROTOCOL  DEVIATIONS  ................................ ................................ ................................ ....................  31 
17.2 INVESTIGATOR / INVESTIGATIONAL  SITE TRAINING  ................................ ................................ ..................  32 
17.3 MONITOR  TRAINING  ................................ ................................ ................................ .........................  32 
17.4 STUDY  MONITORING  ................................ ................................ ................................ ........................  32 
17.5 SITE MONITORING  ................................ ................................ ................................ ...........................  32 
17.6 REGULATORY  AGENCY  INSPECTION  ................................ ................................ ................................ ...... 32 
18.0 ETHICS/PROTECTION OF  HUMAN  SUBJECTS  ................................ ................................ ....................  33 
18.1 ETHICAL  STANDARD  ................................ ................................ ................................ ..........................  33 
18.2 INSTITUTIONAL REVIEW  BOARD /ETHICS  COMMITTEE  ................................ ................................ ..............  33 
ABLATE Post -Appro val Study  
AtriCure Inc. 
Page 5 of 46  CONFIDENTIAL  
Rev. M   
 18.3 INFORMED  CONSENT PROCESS  ................................ ................................ ................................ ...........  33 
18.4 SUBJECT  CONFIDENTIALITY  ................................ ................................ ................................ .................  33 
19.0 DATA HANDLING AND  RECORD  KEEPING  ................................ ................................ .........................  34 
19.1 INVESTIGATOR  RECORDS  ................................ ................................ ................................ ...................  34 
19.2 INVESTIGATOR  REPORTS  ................................ ................................ ................................ ....................  35 
19.3 DATA MANAGEMENT  RESPONSIBILITIES  ................................ ................................ ...............................  36 
19.4 STUDY  RECORDS  RETENTION  ................................ ................................ ................................ ..............  36 
20.0  PROTOCOL  AMENDMENTS  ................................ ................................ ................................ ..............  36 
21.0  TERMINATION OF STUDY OR STUDY  SITE  PAR TICIPCATION  ................................ .............................  36 
22.0  LITERATURE  REFERENCES  ................................ ................................ ................................ .................  38 
APPENDIX A:   ADVERSE  EVENT  DEFINITIONS  ................................ ................................ ................................ .... 39 
ABLATE Post -Appro val Study  
AtriCure Inc. 
Page 6 of 46  CONFIDENTIAL  
Rev. M   
 PROTOCOL SUMMARY  
 
 
Title:  AtriCure Synergy RF Energy Lesions For Non -Paroxysmal Forms Of  
Atrial Fibrillation Treatment During Concomitant On -Pump Cardiac 
Surgery Post -Approval Study (or “ABLATE PAS”)  
Device:  The AtriCure Synergy Ablation System devices included in post 
approval study are:  
• Ablation and Sensing Unit – ASU – RF Generator  
• Source Switch – ASB – allows user to connect multiple AtriCure 
devices to  ASU 
• Surgical Clamps (Handpieces) – AtriCure Isolator Synergy 
Handpieces - Product Codes:  OLL2,  OSL2  
Objective:  The primary objective of this post -approval study is to evaluate 
clinical outcomes in a cohort of patients treated during commercial 
use of the AtriCure Synergy Ablation System by physicians 
performing the Maze IV procedure.  
Design:  This prospective, open label, multi -center, observational, single arm 
registry is designed to mo nitor the AtriCure Synergy Ablation System 
continued safety and efficacy during the peri -procedural and long 
term phase during commercial use in patients being treated for non - 
paroxysmal forms of atrial fibrillation (AF) who are undergoing a 
concomitant o pen, on -pump cardiac surgical procedure.  
Primary Efficacy 
Outcome:  The proportion of patients free from AF (i.e. no episodes lasting > 30 
continuous seconds duration of either Atrial Fibrillation, Atrial 
Flutter or Atrial Tachycardia) while off Class I and III antiarrhythmic 
drugs for at least 4 weeks (except amiodarone which must be 12 
weeks prior to assessment), as determined by an independent core 
lab assessment of 48 hour Holter, Zio™ Patch or PPM interrogation 
recording performed at a minimum of 12,  24 and 36 months 
postoperatively (hypothesis test at 36 months).  
Primary Safety 
Outcome:  • The proportion of patients with any serious device or ablation 
procedure -related adverse events (excluding pacemaker  
implantation)  within 30 days post -procedure or h ospital 
discharge (whichever is later) as adjudicated by a Clinical Events 
Committee.  
ABLATE Post -Appro val Study  
AtriCure Inc. 
Page 7 of 46  CONFIDENTIAL  
Rev. M   
  
 
 
Secondary Efficacy 
Outcome:  • The proportion of patients free from AF, regardless of AAD 
usage (i.e. no episodes lasting > 30 continuous seconds duration 
of either Atrial Fibrillation, Atrial Flutter or Atrial Tachycardia), 
as determined by an independent core lab assessment of 48 
hour Holter, Zio™ Patch or PPM interrogation recording 
performed at a minimum of 12, 24 and 36 months 
postoperatively.  
Secondary Safety 
Outcomes:  • Composite major adverse event: Serious adverse events 
occurring post -operatively within 30 days post -procedure or 
hospital discharge (whichever is later)  including:  
o Death (includes deaths after 30 days or hospital 
discharge if de ath is procedure  related).  
o Stroke (resulting in significant permanent  disability)  
o TIA 
o Myocardial infarction,  and 
o Excessive bleeding (requiring >2 units of blood 
replacement and surgical  intervention).  
• All adverse events that are reported in the study shall  be 
summarized and reported. The events shall be summarized at 
each follow up interval based upon level of seriousness (serious 
vs. non -serious) and attribution (device, ablation procedure, 
primary cardiac surgical procedure or co -morbid condition,  etc.)  
• A separate report of device and ablation procedure -related 
serious adverse events summarized and reported by type of 
primary cardiac surgical procedure (i.e. surgical procedure to 
address structural heart disease) shall also be  performed.  
• Pacemaker implanta tion (PPM) within 30 days post procedure 
will be summarized and reported by reason for PPM (i.e., sinus 
node dysfunction, AV -node,  etc.).  
Planned Enrollment:  Up to 390 subjects.  
Population:  Subjects who have non -paroxysmal forms of AF and are scheduled to 
undergo a primary open cardiac surgical procedure requiring 
cardiopulmonary bypass including valve surgery and/or CABG.  
ABLATE Post -Appro val Study  
AtriCure Inc. 
Page 8 of 46  CONFIDENTIAL  
Rev. M   
  
 
 
Follow -up Schedule:  All patients will undergo clinical follow -up in hospital and at 30 days,  
4, 12, 24 and 36 months post procedure.  
Number of Sites:  50 study centers located in North America  
Study Duration 
(Estimated):  Study Start: Q3/2012  
Enrollment Completion: Q4/2014 
Follow Up Completion: Q4/2017 
Final Report: Q2/2018  
(See detail in section 6.5)  
Inclusion Criteria:  • Age ≥ 18  years.  
 Subjects with Persistent or Longstanding Persistent Atrial 
Fibrillation defined in accordance to HRS AF expert consensus 
statement (2012)  1 
• Persistent AF is defined as continuous AF that is sustained 
beyond seven days. Episodes of AF in which a decision is 
made to electrically or pharmacologically cardiovert the 
patient after > 48 hours of AF, but prior to 7 days, should 
also be classified as persistent AF  episodes.  
• Longstanding persistent AF is defined as continuous AF of 
greater than 12 months  duration.  
o The performance of a successful  cardioversion  (sinus 
rhythm >30 seconds) within 12 months of an 
ablation procedure with documented early 
recurrence of AF within 30 days should not alter the 
classification of AF as long -standing  persistent  
 Subject is scheduled to undergo elective open cardiac surgical 
procedure(s) to be performed on cardiopulmonary bypass for 
one or more of the following: Coro nary Artery Bypass Grafting 
(CABG) , Mitral valve repair or replacement, Aortic valve repair or 
replacement, Tricuspid valve repair or replacement. In 
conjunction with these procedures Patent Foramen Ovale (PFO) 
or A Septal Defect (ASD) repair are  allowed.  
 The patient (or their legally authorized representative) agrees to 
participate in this study by signing the IRB approved informed 
consent  form.  
 Willing and able to return for scheduled follow -up visits.  
ABLATE Post -Appro val Study  
AtriCure Inc. 
Page 9 of 46  CONFIDENTIAL  
Rev. M   
  
 
Exclusion Criteria:  • Stand alone  AF without indication(s) for  concomitant 
cardiac  surgery.  
• Need for emergent cardiac surgery (i.e. cardiogenic 
shock).  
• Preoperative need for an intra -aortic balloon pump or 
intravenous  inotropes  
• Pregnancy or desire to get pregnant for the duration of 
the study (concomitant surgical procedure through the 
thirty six (36) month follow -up period).  
• Enrolled in another clinical trial that could confound  the 
results of this  study.  
 
Sample Size:  The study will enroll up to 390 subjects at 50 North 
American sites.  The 390 patient sample size for this study 
was derived to establish that the rates for the primary 
outcomes of 30 -day serious device and ablation procedure 
related AE and 3 -year efficacy success rates are within the 
pre-established reference rate bounds.  This number of 
subjects shall provide an adequate sample to fully assess 
the outcome of the procedure within a broad population 
and should supply a sufficient number of subjects for both 
30 day safety evaluation (>333 subjects at 30 days)  and 
long term eff icacy evaluation (>275 subjects at 3 years  
Steering Committee:  Patrick McCarthy, MD – Committee Chairperson  
 
Sponsor/Manufacturer, 
Study Coordination and 
Monitoring:  
 
Data Management, 
Safety & Biostatistics:   
AtriCure, Inc.  
6217 Centre Park Drive 
West Chester, OH 45069  
Office Number: (513) 755 -4100 
Boston Biomedical Associates 
386 West Main Street – Suite 7  
Northboro, Massachusetts 01532 
USA 
Office Number: (508) 351 -8632  
Fax Number: (508) 351 -8637  
 
Core Lab:   
Agility Centralized Research Services, Inc. 
A CardioNet Company  
2275 Half Day Road Suite # 133 
Bannockburn, IL 60015  
ABLATE Post -Appro val Study  
AtriCure Inc. 
Page 10 of 46  CONFIDENTIAL  
Rev. M   
  
 
1.0 INTRODUCTION: BACKGROUND INFORMATION AND SCIENTIFIC  RATIONALE  
 
1.1 Background Clinical  Information  
Atrial fibrillation (AF) is  the most common sustained tachyarrhythmia seen in clinical practice, 
particularly in the elderly, and is an important risk factor for stroke. AF accounts for 34% of arrhythmias 
as the principal diagnosis.1 
 
AF is a condition in which there are highly asyn chronous atrial depolarization without effective atrial 
contraction. AF is also characterized by the presence of rapid, irregularly timed impulses reaching the AV 
node from the atrium and is associated with irregularly timed ventricular response. The atria l rate can 
be between 350 to 600 beats per minute. Due to the low pass filtering properties of atrio -ventricular 
(AV) node, the ventricular response is much  slower.  
 
It is estimated that 2.2 to 5.1 million people in the U.S. have AF.2,3 The prevalence of A F increases with 
age. The condition affects fewer than 1% of people under age 60, with nearly 4% of people 60 years and 
older and 9% of people 80 years and older having been diagnosed with AF.4 In 85 -95% of cases, the 
presence of AF is related to the prese nce of underlying heart disease, left atrial enlargement, or 
abnormal atrial electrophysiology.  
 
AF can lead to thromboembolism and stroke in approximately 5 -10% of high -risk patients.5 Risk 
increases with age and with the coexistence of structural heart disease, such as mitral regurgitation, 
which is common in these patients. Because there are no effective atrial contractions, areas of blood 
stasis are set up in the atria (particularly in the appendages) and clot sometimes forms. In about 5% of 
patients w ith AF, clotted blood dislodges from the atria and causes stroke. The American Heart 
Association estimates that in the United States, AF is responsible for over 70,000 strokes each year. In 
just the United States, it is estimated that AF accounts for 1.4 m illion outpatient visits and over 227,000 
hospitalizations per year.2,3 
 
2.0   AtriCure System  
 
The trial is designed as a Post Approval Study to investigate the acute and long -term outcomes of the 
AtriCure Synergy Ablation System. The product has been use d in previously clinical IDE trials (RESTORE 
and ABLATE) that were used to support market approval of the system. The clinical results were 
presented to the FDA Advisory Panel in October of 2011. This group recommended approval this 
product. FDA accepted t heir recommendation and the Synergy Ablation System received approval in 
December 2011. A condition of this approval is to conduct this Post Approval Study aimed at collecting 
information on the acute and longer term outcomes on the product when used to co mplete the MAZE 
IV procedure in a commercial setting.  
ABLATE Post -Appro val Study  
AtriCure Inc. 
Page 11 of 46  CONFIDENTIAL  
Rev. M   
  
 
3.0 ATRICURE SYNERGY ABLATION SYSTEM  LABELING  
 
3.1 Indications for  Use 
The AtriCure Synergy Ablation System is intended to ablate cardiac tissue for the treatment of persistent 
atrial fibrillati on (sustained beyond seven days, or lasting less than seven days but necessitating 
pharmacologic or electrical cardioversion) or longstanding persistent atrial fibrillation (continuous atrial 
fibrillation of greater than 12 months duration) in patients who  are undergoing open concomitant 
coronary artery bypass grafting and/or valve replacement or repair.  
 
3.2 Contraindications  
The AtriCure Synergy Ablation System should not be used for contraceptive coagulation of fallopian 
tubes.  The device is not designed for safe and effective use for that purpose.  
 
3.3 Warnings and  Precautions  
The warnings and precautions can be found in the AtriCure Synergy Ablation System Instructions for 
Use.  
 
4.0 ATRIAL FIBRILLATION  CLASSIFICATION  
In an effort to bring uniformity to the vario us nomenclature being used in the medical community, the 
Heart Rhythm Society Task Force on Catheter and Surgical Ablation (HRS/EHRA/ECAS) have 
recommended the following AF classification scheme based upon the patterns of duration and mode of 
termination1. 
• Paroxysmal AF is defined as recurrent AF ( >2 episodes) that terminates spontaneously within  7 
days. Episode of AF <48 hours duration that are terminated with electrical or pharmacologic 
cardioversion should also be classified as paroxysmal AF  episodes.  
 
• Persistent AF is defined as continuous AF that is sustained beyond seven days. Episodes of AF in 
which a decision is made to electrically or pharmacologically cardiovert the patient after >48 
hours of AF, but prior to 7 days, should also be classified as persistent AF  episodes.  
 
• Longstanding persistent AF is defined as continuous AF of greater than 12 months duration. The 
performance of a successful cardioversion (sinus rhythm >30 seconds) within 12 months of an 
ablation procedure with documented early recurrence of AF with30 days should not alter the 
classification of AF as long -standing  persistent.  
 
The ABLATE Post Approval Study (ABLATE PAS) will focus on those patients with non -paroxysmal 
forms of AF who meet the inclusion/exclusion criteria defined in Section 9 of this protocol.  
• 
5.0   STUDY OBJECTIVE  
The primary objective of this ABLATE Post -Approval Study (or “ABLATE PAS”) is to evaluate clinical 
outcomes in a cohort of patients receiving treatment with the AtriCure Synergy Ablation System in 
performing the Maze IV procedure. The efficacy of the device will be demonstrated by establishing that 
the device effectively eliminates non -paroxysmal forms of atrial fibrillation. Elimination of non - 
paroxysmal forms of atrial fibrillation will be assessed b y a 48 hour Holter Monitor,  Zio™ Patch, or PPM  
ABLATE Post -Appro val Study  
AtriCure Inc. 
Page 12 of 46  CONFIDENTIAL  
Rev. M   
  
 
interrogation performed at 12, 24, and 36 months  after the procedure that demonstrates no signs of 
atrial fibrillation/atrial flutter/ atrial tachycardia longer than 30 seconds as assessed by an independent 
core laboratory.  
 
Safety shall be assessed in the study using the incidence of serious device or ablation procedure related 
adverse events which occur within 30 days post -procedure or hospital discharge (whichever is longer).  
 
6.0 STUDY  DESIGN  
 
The ABLATE PAS is a multi -center, prospective, observational study designed to evaluate the AtriCure 
Synergy Ablation System for continued safety and efficacy during commercial use in a real world settings 
in patients with non -paroxysmal forms of AF. One o f the goals of a post approval study is to assure that 
the provider and subject population are representative of the general population.  
To that end, the following process is being implemented for site selection and enrollment procedures.  
 
6.1 Site Selection  
The ABLATE PAS protocol will be conducted at 50 North American centers. Participating sites will be 
split into three categories, ABLATE AF Registry Subjects, New Users and Existing users. All participating 
sites will have successfully participated in AtriCu re’s training/certification program.  
 
ABLATE AF Registry Centers (N = 20 sites):  
The intent of the ABLATE AF Registry protocol was to provide further supportive data on the 
concomitant MAZE procedure with the AtriCure Synergy Ablation System. To continue t he collection of 
this supportive data, the FDA has approved the transfer of the ABLATE AF Registry subjects into the 
ABLATE PAS protocol. On the date of FDA approval of the ABLATE PAS approval, the ABLATE PAS 
database will be released and the former ABLATE  AF subjects will move into the ABLATE PAS database. 
These subjects will be followed from that date forward per the ABLATE PAS protocol (follow up visits, 
safety endpoints, adjudication through 30 days, and efficacy endpoints). At the time of transition fr om 
the ABLATE AF Registry study to ABLATE PAS, 19 sites had been initiated with 18 centers enrolling.  
ABLATE Post -Appro val Study  
AtriCure Inc. 
Page 13 of 46  CONFIDENTIAL  
Rev. M   
  
 
Existing/ Current Users (currently uses the AtriCure Synergy Ablation System, but did not participate 
in the ABLATE AF Registry; (N=20):  
A total of 20 additional existing/current user centers will be qualified to participate in the ABLATE PAS. 
To identify these potential  current user centers, AtriCure developed a list of all cardiac surgery centers 
in the United States from their marketing database. Potential centers have been identified from this list 
based on the known data from the database against the following criteria:  
a) Performs the MAZE IV procedure using the AtriCure Synergy ablation  system  
b) Performs at least 40 concomitant MAZE surger ies per  year  
c) Has the capability of conducting clinical  research  
d) Capable of performing a three year follow up on the patient  population  
 
A total of thirty US centers were identified as potential CURRENT user centers for the ABLATE PAS study. 
A computer gene rated randomization number will be assigned by the study statistician to each study 
center on the list and this number will then be utilized to order the study centers.  Study centers will 
then be approached in the randomly assigned order and qualified bas ed on the criteria for conducting 
this clinical study in accordance with Standard Operating Procedures for site qualification.  Study 
Centers will continue to be qualified from the randomly ordered list until a total of 20 US centers are 
identified.  
 
New U ser Centers (N=10):  
 
“New Users” are defined as centers that are either hospital that have not performed the MAZE IV 
procedure or have not performed the procedure with the AtriCure Synergy Ablation System. The 
ABLATE PAS protocol will include ten “new user ” centers which were identified through the same list of 
cardiac surgery centers in the United States. However, the filtering process excluded the first bullet 
point “Performs the MAZE IV procedure using the AtriCure RF ablation system.”  
 
 
6.2 Study Center Ini tiation/Start  Up 
The ABLATE PAS will utilize the existing subjects and sites currently involved in the ABLATE AF Registry. 
It is anticipated that at the initiation of ABLATE PAS a total of 75 subjects will be enrolled at the 20 
ABLATE AF sites. It is anticipated that 2 -5 centers will be initiated each month starting in August 2012 
with all sites being active for enrollment by June 2013.  Table 1 and Figure 1 represents the anticipated 
site start up.  
ABLATE Post -Appro val Study  
AtriCure Inc. 
Page 14 of 46  CONFIDENTIAL  
Rev. M   
 
Post Approval Study 
Projected Site Start Up  
50 
 
40 
 
30 
 
20 
 
10 
 
  
 
Table 1:  Projected US Site Start -Up—PAS 
 
Month  Site Approved 
Initiated  Cumulative Sites  
August 2012  20 from Ablate AF  20 
Sept. 2012  2 22 
Oct 2012  2 24 
Nov 2012  3 27 
Dec 2012  3 30 
Jan 2013  3 33 
Feb 2013  3 36 
Mar 2013  4 40 
April 2013  4 44 
May 2013  4 48 
June 2013  2 50 
 
Figure 1:  ABLATE PAS Projected US Site Start Up  
 
 
 
 
 
 
 
      
Sites 
ABLATE Post -Appro val Study  
AtriCure Inc. 
Page 15 of 46  CONFIDENTIAL  
Rev. M   
  
 
6.3 Enrollment  Procedures  
All patients presenting with non paroxysmal  (AF) and who are scheduled to undergo a primary open 
cardiac surgical procedure requiring cardiopulmonary bypass including valve surgery and/or CABG are 
potential study candidates for the ABLATE PAS. Potential patients will be pre -screened to confirm AF 
classification (persistent or longstanding persistent) for eligibility and offered the chance to participate 
in the study. Patients will not undergo any protocol specific assessments that are not considered to be 
standard of care prior to signing the inform ed consent form for the study.  A Patient Screening Log will 
be provided to the study sites, in order to maintain a cumulative log of all screened patients. The reason 
for ineligibility will be documented on the study screening log including patients who r efuse to 
participate in the  study.  
 
Each investigator will recruit subjects equitably in an effort to ensure to the best extent possible that the 
subject pool is representative in gender, race, ethnicity, and age of the population affected by the 
condition  being studied.  
 
The projected enrollment estimates for the ABLATE PAS is provided in Table 2 and Figure 2. It is 
anticipated that the study will be fully enrolled by the fourth quarter of 2014.  
 
Table 2:  ABLATE PAS US Enrollment Projections  
 
 ABLATE 
AF Q3/ 
2012  Q4/ 
2012  Q1/ 
2013  Q2/ 
2013  Q3/ 
2013  Q4/ 
2013  Q1/ 
2014  Q2/ 
2014  Q3/ 
2014  Q4/ 
2014  
Quarterly 
Enrollment   20 20 25 25 30 30 30 30 35 30 
Cumulative 
Enrollment  75 95 115 140 165 195 225 270 310 350 390 
ABLATE Post -Appro val Study  
AtriCure Inc. 
Page 16 of 46  CONFIDENTIAL  
Rev. M   
  
 
Figure 2:  ABLATE PAS US Enrollment Estimates  
 
 
6.4 Informed Consent  Procedures  
Informed consent must be obtained from a potential patient or their legally authorized representative 
prior to conducting any preoperative assessments that are not part of the routine preparation and 
evaluation of a patient for their scheduled open -heart procedure or evaluation of atrial fibrillation, even 
though the patient’s eligibility has not yet been fully established. If during the course of the pre - 
operative evaluations, a treatment patient is found not to be eligible for inclusion in the study, the 
patient or their representative should be notified and the reason for ineligibility documented on the  
screening log.  
 
6.5 PAS Timeline  
Table 3 outlines the projected timeline for the PAS. Based on these enrollment projects, the last subject 
enrolled will be in Q4/2014 and the last three year (36 month) follow up visit would be completed in 
Q4/2017.  The final  study report would be submitted in Q1/2018.  
Post Approval Study Enrollment Estimates  
450  
400  
350  
300  
250  
200  
150  
100  
50 
0 
390  
350  
310  
270  
225  
195  
165  
115  
140  
75 
95 
20 
 20 
 25 
 25 
 30 
 30 
 30 
 30 
 35 
 30 
ABLATE    Q3/   Q4/   Q1/   Q2/   Q3/   Q4/   Q1/   Q2/   Q3/   Q4/ 
AF 2012  2012  2013  2013  2013  2013  2014  2014  2014  2014  
Quarterly Enrollment  
 Cumulative Enrollment  
ABLATE Post -Appro val Study  
AtriCure Inc. 
Page 17 of 46  CONFIDENTIAL  
Rev. M   
  
 
Table 3:  PAS Timeline  
 
 ABLATE 
AF Q3/ 
2012  Q4/ 
2012  Q1/ 
2013  Q2/ 
2013  Q3/ 
2013  Q4/ 
2013  Q1/ 
2014  Q2/ 
2014  Q3/ 
2014  Q4/ 
2014   Q4/ 
2017  Q1/ 
2018  
Quarterl
y Enroll - 
ment   20 20 25 25 30 30 30 30 35 30    
Cumula - 
tive 
Enroll - 
ment  75 95 115 140 165 195 225 270 310 350 390    
Follow 
up Com - 
plete              390 Final 
Report 
Sub- 
mitted  
 
 
7.0 STUDY  OUTCOMES  
The ABLATE PAS will utilize a 48 hour Holter, Zio™ Patch or PPM interrogation performed at follow up 
(12, 24 and 36 month post -procedure interval)  to assess efficacy (i.e. freedom from AF). Additionally, 
secondary efficacy outcomes will be reported through  36 months  post -operatively. The Holter Monitor, 
Zio™ Patch or PPM interrogation data shall be reviewed by an independent Core Laboratory (see Study 
Reference Manual  for Holter Monitor Core Lab Procedures).  
The following are the primary and secondary effi cacy outcomes for this ABLATE Post -Approval Study:  
 
7.1 Primary Efficacy  Outcome  
The proportion of patients free from AF (i.e. no episodes lasting > 30 continuous seconds duration of 
either Atrial Fibrillation, Atrial Flutter or Atrial Tachycardia) while off Class I and III antiarrhythmic drugs 
for at least 4 weeks (except amiodarone w hich must be 12 weeks) prior to assessment), as determined by 
an independent core lab assessment of 48 hour Holter, Zio™ Patch or PPM interrogation recording 
performed at a minimum of 12, 24 and 36 months postoperatively.  
 
7.2 Secondary Efficacy  Outcome  
The pr oportion of patients free from AF, regardless of AAD usage (i.e. no episodes lasting > 30 
continuous seconds duration of either Atrial Fibrillation, Atrial Flutter or Atrial Tachycardia), as 
determined by an independent core lab assessment of 48 hour Holte r, Zio™ Patch or PPM interrogation 
recording performed at a minimum of 12, 24 and 36 months postoperatively.  
 
7.3 Primary Safety  Outcome  
The proportion of patients with any serious device or ablation procedure -related adverse event within 
30 days post -procedur e or hospital discharge (whichever is later).  
ABLATE Post -Appro val Study  
AtriCure Inc. 
Page 18 of 46  CONFIDENTIAL  
Rev. M   
  
 
7.4 Secondary Safety  Outcomes  
In addition to the primary safety outcome discussed above the following safety outcomes will be 
evaluated:  
• Composite major adverse event: Serious adverse events occurring post -operatively within 30 
days of procedure or hospital discharge (whichever is later)  including:  
o Death (includes deaths after 30 days or hospital discharge if death is procedure  related).  
o Stroke (resulting in significant permanent  disability)  
o TIA 
o Myocardial infarction,  and 
o Excessive bleeding (requiring >2 units of blood replacement and surgical  intervention).  
 
All serious adverse events that are reported in the study shall be summarized and reported. The events 
shall be summarized at each follow  up interval based upon level of seriousness (serious vs. non -serious) 
and attribution (device, ablation procedure, procedure to address structural heart disease, co -morbid 
condition, etc.) to provide a complete profile of the acute and long -term safety of  the device and 
procedure.  
 
• Device and ablation procedure -related serious adverse events summarized and reported by type 
of surgical procedure (i.e. surgical procedure to address structural heart  disease).  
• Permanent Pacemaker Implantation (PPM) occurring within 30 days post procedure will be 
summarized and reported by reason for PPM implantation (i.e., sinus node dysfunction, AV 
node, etc.).  
 
8.0 DEVICE DESCRIPTION, POTENTIAL RISK BENEFITS & STUDY  JUSTIFICATION  
 
The approved AtriCure Synergy Ablation System devices included in the ABLATE Post -Approval Study 
are: 
• Ablation and Sensing Unit – ASU – RF Generator  
• Source Switch – ASB – allows user to connect multiple AtriCure devices to  ASU 
• Surgical Clamps (Handpieces) – AtriCure Isolator Synergy Handpieces - Product Codes: OLL2, 
OSL2  
Refer to the Instructions for Use (IFU) for descriptions, indications for use, contraindications, system 
preparation, precautions and warnings.  
 
8.1 Potential Risks and  Benefits  
A summary of the risks and benefits of the AtriCure system are outlined in the product Instructions for 
Use (IFU) which is available in the Study Reference Manual (SRM). Also included in the SRM is a copy of 
the product summary of safety and effectiveness document which provides a complete overview of the 
clinical trial results used to support product approval.  
ABLATE Post -Appro val Study  
AtriCure Inc. 
Page 19 of 46  CONFIDENTIAL  
Rev. M   
  
 
9.0 ELIGIBILITY  CRITERIA  
 
9.1 Subject Inclusion  Criteria  
In order to be eligible to participate in this study, a subject must meet all of th e following criteria:  
• Age ≥ 18  years  
 History of a non -paroxysmal form of atrial fibrillation as defined by the HRS/EHRA/ECAS Consensus 
Statement.  
 
• Persistent AF shall be defined as continuous AF that is sustained beyond seven days. Episodes of 
AF in which a decision is made to electrically or pharmacologically cardiovert the patient after > 
48 hours of AF, but prior to 7 days, should also be classified as persistent AF  episodes.  
• Longstanding persistent AF shall be defined as continuous AF of greater than 12  months 
duration. The performance of a successful cardioversion (sinus rhythm >30 seconds) within 12 
months of an ablation procedure with documented early recurrence of AF with30 days should 
not alter the classification of AF as long -standing  persistent.  
 
Note: For both types of AF, two (2) electrocardiograms (e.g. 12 -lead ECG, Holter, event monitor, 
Implantable Loop Recorder (ILR), Pacemaker, Zio™ Patch, etc.) documenting AF, with 
electrocardiograms taken at least 7 days apart, for subjects with sustained AF ≥7 days. Holter, 
event monitor, ILR, Zio™ Patch or pacemaker recordings need to show continuous AF.  
 Subject is scheduled to undergo elective open cardiac surgical procedure(s) to be performed on 
cardiopulmonary bypass for one or more of the following: C oronary Artery Bypass Grafting , Mitral 
valve repair or replacement, Aortic valve repair or replacement, Tricuspid valve repair or 
replacement. In conjunction with these procedures patent foramen ovale (PFO) or atrial septal 
defect (ASD) repair are  allowed.  
 The patient (or their legally authorized representative) agrees to participate in this study by signing 
the IRB approved informed consent  form.  
 Willing and able to return for scheduled follow -up visits.  
 
9.2 Subject Exclusion  Criteria  
A potential subject who meets any of the following criteria will be excluded from participation in this 
study:  
 Stand alone AF without indication(s) for concomitant cardiac  surgery.  
 Need for emergent cardiac surgery (i.e. cardiogenic  shock).  
 Preoperative need for an intra -aortic b alloon pump or intravenous  inotropes.  
 Pregnancy or desire to get pregnant for the duration of the study (concomitant surgical procedure 
through the thirty six (36) month follow -up period).  
 Enrolled in another clinical trial that could confound the results of this  study.  
 
10.0 REASONS FOR  WITHDRAWAL  
A study subject will be discontinued from participation in the study if:  
ABLATE Post -Appro val Study  
AtriCure Inc. 
Page 20 of 46  CONFIDENTIAL  
Rev. M   
  
• The investigator feels that the subject can no longer fully comply with the requirements of 
the study or if any of the study procedures would not be in the best interest of the  subject.  
Non -compliance will be clearly documented in the subject’s source documentation (i.e., progress 
notes, medical records, etc.)  
• The subject is lost to follow up. A subject will be considered “lost to follow -up” and 
terminated from the study when all of the following criteria have been  met:  
• Failure to complete the remainder of the scheduled study visits without due cause;  and 
• Documentation of three unsuccessful attempts to contact the subject via tel ephone and 
by  certified  mail.  
• The subject wishes to withdrawn their consent for participation in the  study.  
 
11.0  TREATMENT OF  SUBJECTS  
The aim of all AF treatment is a complete bi -atrial MAZE IV procedure. This technique includes 
Pulmonary Vein Isolation (PVI) coupled with lesions made on both the left and right atria. In addition, 
the exclusion/excision of the left atrial appendage is recommended. All procedures must be 
documented on the Procedural Case Rep ort Form. The detailed lesions procedure are summarized in 
Figure 3 and Table 4. For all lesions performed, the energy source utilized and number of ablations 
required for each lesion will be recorded.  
 
Based on the type of concomitant surgery or patient p resentation, it is recognized that there may be 
situations in which some lesions are not able to be performed safely. The requirements for each lesion 
are as follows and further described in Figure 3 and Table 4.  
 
Mandatory Lesions - A protocol deviation w ill be documented for any mandatory left sided lesion that 
is either not performed or performed without utilizing the energy source(s) as described in Table 4.  
 
Recommended and Optional Lesions - - A clinical justification must be provided for any recommen ded 
or optional lesions that are either not performed or performed using an energy source that is different 
than the energy source(s) as described in Table 4. Protocol deviations will be required if a clinical 
justification is not provided. . Note:  Surgeo n’s preference is not considered to be a clinical justification.  
 
 
The investigator should refer to the IFU for details on the product, preparation and usage.  
ABLATE Post -Appro val Study  
AtriCure Inc. 
Page 21 of 46  CONFIDENTIAL  
Rev. M   
  
 
Figure 3:  Lesion Set Diagram  
 
Table 4:  Lesion Set List and Energy Source  
Pulmonary Veins (Mandatory):  
 Lesion  Energy Source  
1 Left PV Isolation (left PVI)  AtriCure Synergy OLL2 or OSL2 Clamp  
2 Right PV Isolation (Right PVI)  AtriCure Synergy OLL2 or OSL2 Clamp  
 
Left side lesions (Mandatory):  
Lesion #  Lesion  Energy Source  
3 Box lesion – “ROOF” line  AtriCure Synergy OLL2 or OSL2 Clamp  
4 Box lesion – “FLOOR” line  AtriCure Synergy OLL2 or OSL2 Clamp  
5 Mitral valve annulus  Initiate lesion with AtriCure Synergy OLL2 or OSL2 Clamp 
(mandatory); completion lesion at level of annulus with AtriCure 
Transpolar Pen or Cryo  
6 Connecting lesion from left atrial 
appendage to the left PVI lesion  AtriCure Synergy OLL2 or OSL2 Clamp  
Right Atrial Lesions( Recommended ; if not performed must provide clinical justification*)  
7 Lesion from  atriotomy to tricuspid 
valve annulus  AtriCure Synergy OLLS or OSL2 Clamp; complete lesion at level of 
annulus with AtriCure Transpolar Pen or Cryo  
8 Ablation of SVC  AtriCure Synergy OLL2 or OSL2 Clamp  
8 Ablation of IVC  AtriCure Synergy OLL2 or OSL2 Clamp  
*If a recommended lesion is not done or an alternate energy source is used, a clinical justification must be provided. Protoc ol 
deviations will be required if a clinical justification is not provided. Note: Surgeon’s preference is not considered to be a clinical 
justification.  
 
ABLATE Post -Appro val Study  
AtriCure Inc. 
Page 22 of 46  CONFIDENTIAL  
Rev. M   
  
 
 
 
OPTIONAL LESIONS#:  
Right side lesions:  
9 Right anterior freewall appendage 
lesion  AtriCure Synergy OLL2 or OSL2 Clamp OR Clamp and AtriCure 
Transpolar Pen/Cryo; OR Cryo  
10 Right atrialappendage  to annulus 
lesion  AtriCure Synergy OLL2 or OSL2 Clamp OR Clamp and AtriCure 
Transpolar Pen/Cryo; OR Cryo  
Left side lesions:  
11 Left atrial appendage lesion  AtriCure Synergy OLL2 or OSL2 Clamp  
If a recommended lesion is not done or an alternate energy source is used, a clinical justification must be provided. Protocol 
deviations will be required if a clinical justification is not provided. Note: Surgeon’s preference is not considered to be a  clinical 
justification.  
ABLATE Post -Appro val Study  
AtriCure Inc. 
Page 23 of 46  CONFIDENTIAL  
Rev. M   
  
 
12.0 CLINICAL  ASSESSMENTS  
Subjects shall be evaluated from the time of the surgical procedure through hospital discharge and at a 
variety of timepoints through the 36 months of follow up (Table 5).  
Table 5: Overall Schedule of Events  
 
 
Assessment   
Pre-        
Procedure/Baseline 
(within 14 days prior 
to procedure)   
 
Procedure  Pre- 
Discharge 
(within 48 
hours prior 
to     
discharge)   
 
30 days  
(+7 days)   
 
4 month  
(+/- 30 days)   
 
12 month  
(+/- 60 days)   
 
24 month  
(+/- 60 days)   
 
36 month  
(+/- 60 days)  
Informed Consent  X        
Medical History  X        
Adverse Event 
Evaluation   X X X X X X X 
Physical 
Assessment  X  X X X X X X 
NYHA Class  X   X X    
Medications  X  X X X X X X 
12 lead ECG1 X  X X X    
Holter Monitor 48 
hr, Zio™ Patch/PPM 
Interrogation2,3       
X  
X  
X 
RBC, WBC, HGB,  
HCT, Platelets  X  X      
INR4 X  X X X X X X 
Pregnancy Test5 X        
Lesion set   X       
Pacing Procedure   X 
(optional)        
Concomitant 
Surgical Procedure   X       
Cardioversion6  X X X X X X X 
 
1 Per HRS/EHRA/ECAS Consensus, two ECGs are required prior to baseline to document the type of AF.  
2 Zio™ Patch or Permanent Pacemaker interrogations can be performed in lieu of 48 hour Holter  
3If patient is deemed a failure by EKG, a Holter, Zio™ Patch or Permanent Pacemaker Interrogation is not re quired 
4 For anticoagulated patients only  
5 Females of childbearing potential defined as females who have not reached menopause and have not been surgically 
sterilized  
6 At physician discretion per standard of care at institution  
ABLATE Post -Appro val Study  
AtriCure Inc. 
Page 24 of 46  CONFIDENTIAL  
Rev. M   
  
 
It is important that this schedule be maintained as closely as possible for all patients. AtriCure 
recognizes that patients may not be able to return for all scheduled visits at precisely the date required, 
and therefore, a period of time in which each visit is allowed. Table 6 describes the schedule of follow 
up visits along with the acceptable visit window. Assessments and/or visits not completed will be 
considered missed visits and a protocol deviation will need to be completed. Assessments and/or visits 
compl eted outside these windows will be considered late visits and therefore a protocol deviation.  
Study visits should be scheduled as close to the early part of the visit time period as possible so that if it 
is necessary to cancel and reschedule the visit, th e visit could still be conducted in the required time 
period.  
 
Table 6: Schedule of Follow -up Visits and Time Periods  
 
Visit  Follow -up Window  
Pre-procedure/Baseline  Within 14 days prior to procedure  
Pre-Discharge  No more than 48 hours prior to hospital discharge  
30 days  30 days +7 days  
4 months  120 days +/ - 30 days  
12 months  365 days +/ - 60 days  
24 months  730 days +/ - 60 days  
36 months  1095 days +/ - 60 days  
 
12.1 Repeat Ablation and/or Cardioversion  Procedures  
All information regarding any repeat catheter ablations (reason for the re -do as well as location) or any 
cardioversions will be collected and documented in the CRF. The most prevalent post -procedure rhythm 
will also be documented and recorded in the CRF.  
12.2 Permanent Pacemaker Implantations  (PPM) 
Information regarding PPM implantation within 30 days of the procedure will be collected and 
documented in the CRF, including time of implant and reason.  
 
12.3 Standardization of Anti -arrhythmic Drug Use during Follow -up Period  
Postoperative use of anti-arrhythmic drugs (AAD) following atrial fibrillation surgery varies significantly 
among sites and among clinicians at individual sites. In addition, regulation of the medical regimen may 
be under the direction of the surgeon, the referring clinical ca rdiologist or both in collaboration. Since 
no specific data are available to prove efficacy of any given approach, this shall be left up to the 
discretion and ordinary practice of the investigators. This will not influence the primary efficacy 
outcomes ana lysis, since efficacy will be evaluated after AAD washout.  
The presence or absence of atrial fibrillation shall be assessed in each treatment subject pre-discharge 
(not more than 48 hours prior to discharge) and at the 30 day, 4 month, 12 month, 24 and 36 months 
post -operative visits. Between discharge and the 4 month visits, the investigator or their referring 
cardiologist should see patients who are continuing in AF.  Effective communication between the  
ABLATE Post -Appro val Study  
AtriCure Inc. 
Page 25 of 46  CONFIDENTIAL  
Rev. M   
  
 
investigator and the referring cardi ologist is essential to ensure protocol procedures and required are 
followed when medically possible. An email will be sent to the site prior to each subject’s follow up visit 
as a reminder to contact the referring cardiologist for an update on the subject ’s medications, any 
cardioversions/repeat ablations, rhythm status, etc.  
 
In addition, some subjects may present for medical care between or at scheduled visits, at which time 
AF may be discovered. If a patient is in AF during the follow -up course, additional attempts at medical 
management and cardioversion/catheter ablation can  be undertaken as medically indicated. However, 
every effort should be made to discontinue AADs at least 4 weeks (except amiodarone which must be 
discontinued 12 weeks prior to assessment) prior to the Holter, Zio™ Patch or PPM interrogation 
evaluations at 12, 24, and 36 month follow -up visits . If AADs cannot be discontinued at least four (4) 
weeks (12 weeks for amiodarone) before the 12 month visit  the subject will, by definition not be 
considered a primary efficacy outcome success.  
 
13.0 ASSESSMENT OF  SAFETY  
 
13.1 Adverse  Events  
During each clinical follow -up, the investigator or designee will determine adverse event (AE) 
occurrences. An adverse event is any untoward medical occurrence (signs, symptoms, abnormal 
laboratory findings) in a patient regardless of relati onship to the device or procedure. Each adverse 
event is considered to be either anticipated or unanticipated as described below. The site is required to 
report all adverse events that occur in the study.  
 
13.2 Anticipated Adverse  Events  
A variety of complicati ons are expected to occur in subjects undergoing treatment for atrial fibrillation 
with the AtriCure Synergy Ablation System concomitant with an open -heart procedure requiring 
cardiopulmonary bypass.   These anticipated adverse events are provided in Appen dix A.  
 
These events shall also be classified according to the suspected causality by the study investigator. 
Causality can be attributed to the device, the surgical procedure or to the subject’s underlying disease 
according to the definitions below.  
Devic e Related Adverse Event : An adverse event, which in the judgment of the Investigator, results 
from use of the AtriCure Synergy Ablation System.  
Ablation Procedure Related Adverse Event : An adverse event which, in the judgment of the 
Investigator, results a s a consequence of the ablation procedure and is not specifically related to use of 
the AtriCure Synergy Ablation System.  
Surgical Procedure Related Adverse Event : An adverse event which, in the judgment of the 
Investigator, results as a consequence of the  surgical procedure to address underlying structural heart 
disease and is not specifically related to use of the AtriCure Synergy Ablation System or the ablation 
procedure.  
ABLATE Post -Appro val Study  
AtriCure Inc. 
Page 26 of 46  CONFIDENTIAL  
Rev. M   
  
 
Underlying Disease Related Adverse Event : An adverse event which, in the judgment of the 
Investigator, results as a consequence of the subject’s underlying medical condition and is related to 
neither the ablation nor structural heart disease surgical procedures nor to use of the AtriCure Synergy 
Ablation System.  
 
If the Investigator cannot determine the cause of the event, it should be classified as unknown.  
 
13.3 Events that do not require reporting to the  sponsor  
For purposes of this study, the following events will not be required to be reported as adverse events to 
the spo nsor, because they are normally expected to occur in conjunction with surgical treatment for 
non-paroxysmal forms of atrial fibrillation procedures (Maze IV) or are associated with customary, 
standard care of patients undergoing cardiac surgery:  
• Chest pain  without associated ECG  changes  
• Post -operative  pain  
• Post -anesthesia emesis, nausea, or headache (within 24 hours of  procedure)  
• Electrolyte imbalance without clinical sequelae following procedure, even if requiring  correction  
• Pre - planned future surgical  procedures  
• Low grade temperature increase (101°F or  38.5°C)  
• Dizziness: Imprecise term commonly used to describe various symptoms such as faintness, 
giddiness, imbalance, lightheadedness, unsteadiness or  vertigo.  
• Elevated white blood count, outside the stan dard laboratory normal value, without signs and 
symptoms of  infection  
• Post -operative hematocrit decrease from baseline measured in the OR, prior to the first incision, 
not associated with hemodynamic changes, remaining above 25% and requiring < 3 units  PRBC’s 
• Minor, localized tenderness, swelling, induration, oozing, etc. at surgical  site. 
• Sinus bradycardia/tachycardia that does not require treatment or  intervention  
• Systolic or diastolic blood pressure changes that do not require treatment or  intervention.  
• Any blood transfusions during preplanned operative procedures and unrelated to an adverse 
event.  
• Thrombocytopenia: does not become an AE until treatment is  administered.  
• Atelectasis - collapse of lung tissue affecting part or all of one lung; the alveoli a re deflated. This 
is not considered to be an AE unless treatment other than chest PT is required or it prolongs 
hospitalization.  
• Hyperglycemia - The use of insulin in the post -operative period does not constitute 
hyperglycemia if during the same hospitaliz ation. An elevated blood sugar of less than 250 
mg/dl during the first 48 hours post -operative does not constitute  hyperglycemia.  
• Pleural effusion is not an event unless treatment with thoracentesis or chest tube insertion is 
required  
• Pericardial effusion without hemodynamic compromise or  treatment  
ABLATE Post -Appro val Study  
AtriCure Inc. 
Page 27 of 46  CONFIDENTIAL  
Rev. M   
  
• Atrial Fibrillation /Atrial Flutter/Atrial Tachycardia with or without cardioversion. Note: the 
occurrence of AF is reported as an outcome in the study and documented on a follow up visit 
CRF.  
 
13.4 Serious Adverse  Events  
All SAEs must be reported to AtriCure or designee within 24 hours of investigational site knowledge of 
the event. The event shall be reported through the EDC system. In the event that the EDC system is not 
in service, a paper copy of th e AE CRF must be faxed to Boston Biomedical Associates at (508) 351 -8637 
within 24 hours of knowledge of the event.  
 
A serious adverse event (SAE) is any untoward medical occurrence that:  
 
• Results in  death  
• Is life-threatening  
• Requires inpatient hospitalization or prolongation of existing  hospitalization  
• Results in persistent or significant disability/incapacity,  or 
• Is an important medical event which may jeopardize the subject and may require medical or 
surgical intervention to prevent one of the  above  outcomes  
 
The Investigator at each participating center is ultimately responsible for reporting adverse events 
(complications) to AtriCure or its designated CRO. Investigators must report SAEs within 24 hours of 
investigational site knowledge of eve nt occurrence by entering data into the Case Report Form in the 
electronic database. The Investigator is required to complete the adverse event Case Report Forms at 
each study visit, if an adverse event occurs. One adverse event CRF must be completed for e ach adverse 
event.  
All adverse events will be reported to FDA at least annually.  
 
14.0 Clinical Events Committee (CEC)  
An independent group of physicians that are not involved in the clinical investigations will act as the 
Clinical Events Committee (CEC) under the direction of Boston Biomedical Associates.  The CEC will be 
responsible for the review and validation of report ed potential ENDPOINT adverse events (i.e.: all 
device/procedure related SAEs) that occur within 30 days post procedure per the CEC Charter. The CEC 
shall classify each of these adverse events based on severity and association to the device and/or 
procedur e. During the review of the events, the CEC will be blinded to the clinical site as much as 
possible. The CEC Charter will be developed prior to the start of study enrollment. This charter shall 
include consistent definitions for each type of event and sha ll outline the review process.  
ABLATE Post -Appro val Study  
AtriCure Inc. 
Page 28 of 46  CONFIDENTIAL  
Rev. M   
  
 
15.0 MEDICAL DEVICE  REPORTING  
 
15.1 Manufacturer Reporting  Requirements  
The AtriCure Synergy Ablation System is commercially available and subject to FDA Medical Device 
Reporting (MDR) regulations.  These regulations require manufacturers who receive complaints of 
device malfunctions, serious injuries or deaths associated with  medical devices to notify FDA of the 
incident. AtriCure will comply with the MDR requirements for devices used in this study through the 
information gathered on the case report forms and source documents obtained from the site. If there is 
a device malfun ction or other observation, the Device Observation CRF requires the Investigator to 
notify AtriCure immediately and indicate if the observation resulted in an adverse events and indicate if 
complications are related to the device, procedure or underlying d isease. The collective information 
required on AtriCure MDR procedure forms are designed to comply with time sensitive reporting 
requirements.  AtriCure will submit MDR reports according to 21 CRF parts 803.50 through 803.58.  
In the event of an MDR, the si te should contact: 
AtriCure, Inc.  
Complaints/MDR Reporting 
6217 Centre Park Drive 
West Chester, OH 45069  
Telephone:  513-755-4570  
Fax Number:  513-644-1379  
 
16.0 STATISTICAL  CONSIDERATIONS  
 
16.1 Statistical  Overview  
The purpose of this study is to evaluate continued s afety and efficacy of the AtriCure Synergy Ablation 
System during commercial use in real world settings for surgical ablation of non -paroxysmal atrial 
fibrillation during concomitant cardiac surgical procedures.  
16.2 Analysis  Populations  
The primary analysis population will consist of patients who received the AtriCure Synergy Ablation 
System for treatment of non -paroxysmal atrial fibrillation in the setting of a concomitant cardiac surgical 
procedure.  Other sub -populations will be detailed in the statistical  analysis plan.  
The primary study outcomes will also be stratified according to primary cardiac surgical procedure type, 
e.g.:  
(1) CABG  
 
(2) Aortic  Valve  
 
(3) Mitral  Valve  
 
(4) Tricuspid Valve,  and 
ABLATE Post -Appro val Study  
AtriCure Inc. 
Page 29 of 46  CONFIDENTIAL  
Rev. M   
  
 
(5) Multiple  procedures  
 
We will stratify enrolled subjects by  type of primary cardiac surgical procedure to assure a reasonable 
precision of the estimate for serious device or procedure related SAEs within each specified stratum.  
In addition, primary study outcomes will be stratified by “new users” versus “existing users”. A “new 
user” is defined as a site that has not performed the Maze IV procedure in the past, or has not 
performed the procedure with the AtriCure Synergy Ablation  System. An “existing user” is defined as a 
site that performs the MAZE IV procedure using the AtriCure Synergy Ablation System.  
 
16.3 Sample Size Calculations and  Assumptions  
The study will enroll up to 390 subjects at 50 North American centers. This number of  subjects shall 
provide an adequate sample to fully assess the outcome of the procedure within a broad population.  
The patient sample size for this study was derived to establish that the rates for the primary outcomes 
of 30 -day serious device and ablation  procedure related AE and 3 -year efficacy success rates are within 
the pre -established reference rate bounds. This number of subjects shall provide an adequate sample to 
fully assess the outcome of the procedure within a broad population and should supply a sufficient 
number of subjects for both 30 day safety evaluation (>333 subjects at 30 days) and long term efficacy 
evaluation (>275 subjects at 3 years). Should the statistical power be sufficient with fewer than 390 
subjects (at least 333 subjects at 30 days), PAS will stop recruitment early and continue to follow those 
subjects currently enrolled.  
 
 
16.4 Safety  
The primary safety objective of the ABLATE Post Approval Study (ABLATE PAS) is to demonstrate that 
the serious device and ablation procedure related A E rate (excluding pacemaker implantation) within 30 
days or prior to discharge (whichever is later) of the AtriCure Synergy Ablation System is no worse than a 
performance goal derived from the non -paroxysmal AF subject cohort of the combined AtriCure IDE 
ABLATE and ABLATE AF clinical  trials.  
The rate of serious device or ablation procedure related adverse events (excluding pacemaker 
implantation) within 30 days or prior to discharge (whichever is later) in the non -paroxysmal AF subject 
cohort of the combine d AtriCure IDE ABLATE and ABLATE AF clinical trials was 6.25% (4/64).  
 
The acceptable upper limit of the serious device and ablation procedure related AE rate for the ABLATE 
PAS trial (i.e. the performance goal) is established at 10%.  
The primary safety hy potheses for this study are stated as follows:  
H0 : πPAS_SAFETY ≥ 10%  
H1 : πPAS_SAFETY < 10%  
Using a one -sided exact binomial test for proportions at the 0.05 overall level of significance, a total of 
333 subjects are required to demonstrate that the 30 day serious device or procedure related AErate  
ABLATE Post -Appro val Study  
AtriCure Inc. 
Page 30 of 46  CONFIDENTIAL  
Rev. M   
  
 
(excluding pacemaker implantatio n) in subjects treated with the AtriCure Synergy Ablation System is < 
10% (the performance goal) with 80% power. This calculation was completed using PASS 2008 Power 
and Sample Size Software by NCSS.  
A maximum of 15% Loss to Follow -Up (LTFU) is anticipated  through 30 days, as such the sample size for 
enrollment is increased to 390 subjects to ensure a minimum of 333 subjects are available for 
assessment of the primary safety endpoint through 30 days. Should LTFU be less than 15%, enrollment 
will stop early given the safety endpoint is powered to at least 80%.  
16.5 Efficacy  
Based on data collected from the non -paroxysmal AF subject cohort of the AtriCure IDE ABLATE clinical 
trial it is estimated that approximately 55 -60% of patients treated with the AtriCure Syner gy Ablation 
System will be free of AF while off AADs at 2 -3 years follow -up, where free of AF is defined as no episode 
of atrial fibrillation, atrial flutter or atrial tachycardia lasting longer than 30 seconds. This estimate is 
based on the 57.8% success rate (26/45) seen at an average follow -up time of 20 months in the subset 
of non -paroxysmal AF subjects treated under the AtriCure IDE ABLATE  trial.  
 
The goal of the ABLATE PAS will be to show that the efficacy success rate in patients treated with the 
AtriCure Synergy Ablation System is no lower than a performance goal of 47.8%. This bound of 47.8% is 
established based on the 57.8% success rate (26/45) seen at an average follow -up time of 20 months in 
the subset of non -paroxysmal AF subjects treated under the AtriCure IDE ABLATE trial.  
 
An additional pre -specified margin of 10% is utilized, consistent with the pre -specified margin used in 
the ABLATE clinical trial to establish efficacy. This 10% margin is added to the target rate for purposes of 
defining the acceptable lower limit of the serious device and ablation procedure related AE rate for the 
trial (i.e. the performance goal), resulting in an acceptable one -sided lower 95% confidence interval limit 
of 47.8% for the AF free and off AADs at 3 years pos t-procedure success rate in the ABLATE PAS  trial.  
The primary efficacy hypotheses for this study are stated as follows: 
H0 : πPAS_EF   ≤ 0.478  
H1 : πPAS_EF  > 0.478  
 
Assuming a success rate of 57.8% and a loss to follow -up that only leaves 250 of the initi al 390 patients 
evaluable at 3 years, this test of efficacy superiority with a significance level of 0.05 can be shown with  
94% power . Since this is even greater than 90% power , the ABLATE PAS sample size is driven by the 
safety primary endpoint.  
 
16.6 Statisti cal Analyses 
Primary  Analysis  
Serious device and ablation procedure related AE rates and confidence intervals will be summarized at 
discharge, 30 days, and 1 -year with a hypothesis test performed on the cumulative 30 day serious device  
ABLATE Post -Appro val Study  
AtriCure Inc. 
Page 31 of 46  CONFIDENTIAL  
Rev. M   
  
 
and ablation procedure related AE rate. The primary safety hypothesis test will be conducted using a 
one-sided exact binomial test for proportions at the 0.05 overall level of significance.  
The efficacy outcome rate of freedom from AF, off antiarrhythmic drugs  along with confidence intervals 
will be summarized at 1, 2 and 3 years (i.e. 12. 24, 36 month follow -up), with a hypothesis test 
performed on the 3 -year success outcome. The primary efficacy hypothesis test will be conducted using 
a one -sided exact binomi al test for proportions at the 0.05 overall level of significance.  
Secondary Analysis  
 
Secondary outcomes will be summarized for the analysis population and certain sub -populations. Two - 
sided 95% confidence intervals will be calculated for all presented rates. Descriptive analyses will be 
provided for patient demographics, clinical device/procedural success, medical histories, and co - 
morbidities. Logistic regression analyses may be used to screen a wide range of parameters for their 
association with some  outcomes.  
Procedures to Account for Missing Data  
 
Reasonable efforts will be made to obtain complete data for all patients; however, missing observations 
will occur due to patients lost to follow -up or noncompliance with required assessments. The reasons 
for missing data will be evaluated (e.g. patient is deceased, lost to follow up, missed visit, etc.). In 
addition, the distribution of prognostic factors between patients with data and those without data will 
be examined to evaluate any potential sources o f bias.  
Any missing observations will be described in detail and evaluated for assessment of possible bias. For 
the primary analysis of safety and efficacy outcomes, missing data will be imputed using multiple 
imputation methods (e.g. SAS PROC MI). Additio nal sensitivity analyses of missing data including 1) 
considering everyone who was a failure at last visit also a failure at 3 years and multiple imputation on 
everyone who was a success at last visit, 2) including everyone LTFU as a failure and 3) a tippi ng point 
analysis  will also be performed.  
 
 
17.0 QUALITY CONTROL AND QUALITY  ASSURANCE  
 
17.1 Protocol  Deviations  
A protocol deviation is a failure to comply with the requirements specified within this clinical study 
protocol. Examples of protocol deviations may inc lude enrollment of a study patient who does not meet 
all of the inclusion/exclusion criteria specified in the protocol and missed study visits without 
documentation. Each investigator shall conduct this clinical study in accordance with this clinical study  
protocol, regulatory body regulations, ISO guidelines, Good Clinical Practices, and any conditions of 
approval imposed by their IRB.  
 
All deviations are reviewed and assessed for their impact on patient safety by AtriCure or designee. The 
site PI and stud y staff is responsible for knowing and adhering to their IRB/EC reporting requirements.  
ABLATE Post -Appro val Study  
AtriCure Inc. 
Page 32 of 46  CONFIDENTIAL  
Rev. M   
  
 
The protocol deviations for this protocol consist of, but not limited to the following:  
• Failure to obtain patient’s informed consent prior to any study -related activities and the index 
procedure  
• Use of other approved devices for the ablation procedure or MAZE IV procedure, or lesion set 
deviations.  
• Failure to conduct protocol required clinical  follow -ups 
• Failure to conduct protocol required clinical  follow -ups within time  windows  
• Failure to report serious adverse events according to protocol  requirements.  
 
In the event of any deviation from the protocol, the Investigator will be notified of the site’s non - 
compliance. Corrective actions will be requi red, if necessary. Continued protocol deviations despite re - 
education of the study site personnel or persistent protocol deviation may result in termination of the 
site’s study participation. Patients already enrolled at these sites will continue to be fo llow per the 
clinical protocol.  
 
17.2 Investigator / Investigational Site  Training  
AtriCure and/or designated CRO will be responsible for providing training to the investigator and 
appropriate clinical site personnel.  
 
17.3 Monitor  Training  
AtriCure and/or designated monitors will be trained appropriately to monitor study progress including 
but not limited to the protocol and CRFs . 
 
17.4 Study  Monitoring  
A study specific monitoring plan will be conducted to ensure protocol compliance and applicable 
regulatory req uirements.  
 
Clinical monitors will verify patient data and ensure compliance with GCP, clinical protocol and other 
study requirements, according to the guidelines set forth in the monitoring Standard Operating 
Procedures (SOP) and ISO 14155 guidelines to b e utilized for the study.  
 
17.5 Site Monitoring  
AtriCure or designee may conduct periodic compliance assessments at various study sites. AtriCure or 
designee may request access to all trial records including source documentation for inspection and 
photocopying during a compliance assessment. The Investigator and research coordinator must be 
available to respond to reasonable requests and queries made during the compliance assessment 
process.  
 
17.6 Regulatory Agency  Inspection  
In the event that an investigator is cont acted by a regulatory agency regarding this trial, the investigator 
will notify AtriCure or its designee immediately. The investigator and research coordinator must be 
available to respond to reasonable requests and queries made during the inspection proce ss. The  
ABLATE Post -Appro val Study  
AtriCure Inc. 
Page 33 of 46  CONFIDENTIAL  
Rev. M   
  
 
investigator must provide AtriCure or designee with copies of all correspondence that may affect review 
of the current trial (e.g., Form FDA 483, Inspectional Observations and Warning Letters). AtriCure may 
provide needed assistance  in responding to regulatory audits.  
 
18.0 ETHICS/PROTECTION OF HUMAN  SUBJECTS  
 
18.1 Ethical  Standard  
The investigator will ensure that this study is conducted in full conformity with the principles set forth in 
The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research, 
as drafted by the US National Commission for the Protection of Human Subjects of Biomedical and 
Behavioral Research (April 18, 1979) and codified in 45 CFR Part 46 and/or the ICH E6; 62 Federal 
Regulations 25691 (1997), the Declaration of Helsinki, CIOMS, and the International Ethical Guidelines 
for Biomedical Research Involving Human Subjects (2002).  
 
18.2 Institutional Review Board/Ethics  Committee  
Each participating institution must provide for the review and approval of this protocol and the 
associated informed consent documents and recruitment material by an appropriate Ethics 
Committee(EC)/Institutional Review Board (IRB). Any amendments to the protocol or consent materials 
must also be approved before they are placed into use.  
 
18.3 Informed Consent  Process  
Informed consent is a process that is initiated prior to the individual’s agreeing to participate in the 
study and continues throughout the individual’s study participation. Extensive discussion of risks and 
possible benefits of this therapy will be provided to the subjects and their families. Consent forms 
describing in detail the study interventions/products, study procedures, and risks are given to the 
subject and written documentation of informed consent is  required prior to starting intervention/ 
administering study product. Consent forms will be IRB -approved and the subject will be asked to read 
and review the document. Upon reviewing the document, the investigator will explain the research 
study to the su bject and answer any questions that may arise.  The subject will sign the informed 
consent document prior to any procedures being done specifically for the study. The subjects should 
have the opportunity to discuss the study with their surrogates or think about it prior to agreeing to 
participate.  The subjects may withdraw consent at any time throughout the course of the trial.  A copy 
of the informed consent document will be given to the subjects for their records. The rights and welfare 
of the subjects w ill be protected by emphasizing to them that the quality of their medical care will not 
be adversely affected if they decline to participate in this study.  
 
18.4 Subject  Confidentiality  
Subject confidentiality is strictly held in trust by the participating investigators, their staff, and AtriCure 
and their agents. This confidentiality is extended to cover testing of biological samples and genetic tests 
in addition to the clinical information relating to participating subjects.  
ABLATE Post -Appro val Study  
AtriCure Inc. 
Page 34 of 46  CONFIDENTIAL  
Rev. M   
  
 
The study proto col, documentation, data, and all other information generated will be held in strict 
confidence. No information concerning the study or the data will be released to any unauthorized third 
party without prior written approval of the sponsor.  
 
The study moni tor or other authorized representatives of the AtriCure may inspect all documents and 
records required to be maintained by the investigator, including but not limited to, medical records 
(office, clinic, or hospital) and pharmacy records for the subjects i n this study. The clinical study site will 
permit access to such records.  
 
19.0 DATA HANDLING AND RECORD  KEEPING  
Each participating site will maintain appropriate medical and research records for this trial, in 
compliance with ICH E6, Section 4.9 and regulatory  and institutional requirements for the protection of 
confidentiality of subjects. As part of participating in a manufacturer -sponsored study, each site will 
permit authorized representatives of the sponsor(s), BBA,  and regulatory agencies to examine (and 
when required by applicable law, to copy) clinical records for the purposes of quality assurance reviews, 
audits, and evaluation of the study safety and progress.  
 
Source data are all information, original records of clinical findings, observations, or oth er activities in a 
clinical trial necessary for the reconstruction and evaluation of the trial.  
 
The investigator is responsible to ensure the accuracy, completeness, legibility, and timeliness of the 
data reported. All source documents should be completed  in a neat, legible manner to ensure accurate 
interpretation of data. Dark ink is required to ensure clarity of reproduced copies. When making 
changes or corrections, cross out the original entry with a single line, and initial and date the change.  
DO NOT ERASE, OVERWRITE, OR USE CORRECTION FLUID OR TAPE ON THE ORIGINAL.  
 
19.1 Investigator  Records  
Investigators will maintain complete, accurate and current study records. Records shall be maintained 
during the clinical study and for two years after the later of th e date on which the study is terminated or 
completed, or the date the records are no longer required to support FDA approval of the device.  
Investigator records shall include the following materials:  
o Correspondence : Documentation of all verbal and written correspondence with FDA, AtriCure, 
the Clinical Monitor, the Clinical Events Committee (CEC), and other investigators regarding this 
clinical study or any patient enrolled  therein.  
o Subject records : Signed informed consent forms, copies of all completed Cas e Report Forms and 
supporting documents (laboratory reports, reports of diagnostic tests, medical records, etc.)  and 
records of exposure of each subject to the device. Informed consent must comply with FDA 
regulations (21 CFR, part  50). 
 
 
ABLATE Post -Appro val Study  
AtriCure Inc. 
Page 35 of 46  CONFIDENTIAL  
Rev. M   
  
 
o Investigational Plan (Clinical Study Protocol) : A current copy of the Clinical Study Protocol 
including Instructions for Use of the AtriCure Synergy Ablation System and blank case report 
forms.  
o Institutional Review Board (IRB)/Ethics Committee (EC) Information : All information pertaining 
to IRB/EC review and approval of this clinical study including a copy of the IRB/EC letter 
approving the clinical study, a blank informed consent form approved by the IRB/EC, and 
certification from the IRB/EC Chairma n that the IRB/EC complies with FDA regulations (21CFR, 
Part 56)/regulatory body regulations, and that the IRB/EC approved the clinical study protocol 
based on the Report of Prior  Investigations.  
o Investigator Agreements : Copies of signed Investigator, Co -investigator and Sub -Investigator 
Agreements with accompanying curriculum  vitae.  
o Other : Any other records that may be required by applicable state or federal  laws.  
 
19.2 Investigator  Reports  
The Investigator will prepare and submit the following reports:  
o MDR: Medical Device Reporting of all events related to the device or device  malfunctions.  
o Withdrawal of IRB Approval : Withdrawal of approval shall be reported to AtriCure or designee 
within five working days. The Investigator will provide a written report of th e reason(s) approval 
was withdrawn.  
o Progress Reports : The Investigator will submit progress reports to AtriCure or designee in the 
form of completed Case Report Forms. The same forms will be used at all Investigative Centers 
for the recording of data on th e findings of follow -up evaluations and complications. In 
addition, the Investigator may be asked to submit progress reports to AtriCure or designee and 
the reviewing IRB that include the number of study subjects, a summary of follow -up data and 
complicati ons and a general description the study  progress.  
o Final Report : The investigator shall submit a final report within three months of termination or 
completion of the study or that Investigator’s participation in the study, to AtriCure or designee 
and the IR B. 
o Other Reports : Upon the request of FDA, the reviewing IRB, or AtriCure or designee, the 
Investigator will provide accurate and timely information about any aspect of the clinical  study.  
o Deviations from the Study Protocol : The Investigator shall notify AtriCure or designee and the 
reviewing IRB of any deviation from the Clinical study protocol intended to protect the life or 
physical well being of a patient in an emergency. Such notice shall be given as soon as possible, 
but in no event later than five working days after the emergency occurred. Except in such an 
emergency, prior approval of AtriCure is required for any deviation from the Clinical study 
protocol. Approval from the FDA and the reviewing IRB is also required if these changes or 
deviations are expected to affect the rights, safety or welfare of human  subjects.  
ABLATE Post -Appro val Study  
AtriCure Inc. 
Page 36 of 46  CONFIDENTIAL  
Rev. M   
  
 
19.3 Data Management  Responsibilities  
Electronic Case Report Forms are used for the collection and recording of data at all Investigative 
Centers . Investigators are responsible for the timely completion and updating the electronic case report 
form database (enrollment form should be completed within 24 hours of the concomitant surgical 
procedure; follow up visits should be completed within 5 workin g days of the corresponding study visit. 
SAEs to be reported within 24 hours of knowledge of the event).  
 
Incoming data are reviewed to identify inconsistent or missing data and adverse events. Data issues will 
be addressed within the EDC system with the i nvestigative Centers and/or during site visits. All hard 
copy forms and data files will be secured to ensure confidentiality.  
 
19.4 Study Records  Retention  
Study documents should be retained for a minimum of 2 years after the last approval of a marketing 
applic ation in an ICH region and until there are no pending or contemplated marketing applications in an 
ICH region or until at least 2 years have elapsed since the formal discontinuation of clinical development 
of the product. These documents should be retained  for a longer period, however, if required by local 
regulations. No records will be destroyed without the written consent of the sponsor, if applicable. It is 
the responsibility of the sponsor to inform the investigator when these documents no longer need to be 
retained.  
 
20.0  PROTOCOL  AMENDMENTS  
Approved protocol amendments were  provided to investigators by AtriCure or its designee prior to 
implementation. The site Investigator was responsible for notifying the IRB of the protocol amendment 
with administrative changes or obtaining IRB approval of the protocol amendment with changes in 
patient care or safety, according to instructions provided by AtriCure or its designee with the pro tocol 
amendment. Institutional Review Board acknowledgements and approvals must be documented in 
writing prior to implementing protocol amendments.  Copies of this documentation must also be 
provided to AtriCure or its designee.  
 
21.0  TERMINATION OF STUDY OR STUDY SITE  PARTICIPCATION  
AtriCure may terminate the study at any time. If the study is terminated prior to the completion of 
expected enrollment for any reason, all participating centers will be notified within five working days. 
All patients already enrolled will continue to be followed for the planned course of study described in 
this protocol. The study shall be terminated following the final follow -up visit of the last enrolled 
patient.  
 
AtriCure reserves the right to terminate study site participa tion and remove appropriate study materials 
at any time. Specific instances that may precipitate such termination include but are not limited to the 
following:  
 
 Failure to meet minimum patient enrollment  requirements  
ABLATE Post -Appro val Study  
AtriCure Inc. 
Page 37 of 46  CONFIDENTIAL  
Rev. M   
  
 Failure to comply with p rotocol specified procedures and  documentation  
 
 Failure to comply with Good Clinical  Practice  
 
The site Investigator may also discontinue study participation with suitable written notice to AtriCure.  
ABLATE Post -Appro val Study  
AtriCure Inc. 
Page 38 of 46  CONFIDENTIAL  
Rev. M   
  
 
22.0  LITERATURE  REFERENCES  
1. 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial 
Fibrillation: Recommendations for Patient Selection, Procedural Techniques, Patient 
Management and Follow -up, Definitions, Endpoints and Research Trial Design. 2012 Heart 
Rhythm  Society  
2. Peters NS et al., Atrial Fibrillation: strategies to control, combat and cure.  Lancet;  2002:359:593 -603 
3. American Heart Association. Heart Disease and Stroke Statistics – 2006 Update. Circulation. 2006; 
113:e85 -e151.  
4. Secular Trends in Incide nce of Atrial Fibrillation in Olmsted County, Minnesota, 1980 to 2000, and 
Implications on the Projections for Future Prevalence, Yoko Miyasaka, Marion E. Barnes, 
Bernard J. Gersh, Stephen S. Cha, Kent R. Bailey, Walter P. Abhayaratna, James B. Seward and 
Teresa S.M. Tsang. Circulation 2006; 114;  119-125.  
5. Brown, DL et al “Projected costs of ischemic stroke in the United States” Neurology. 2006;  67:1 -1. 
6. Di Tullio MR, Homma S. Mechanisms of cardioembolic stroke. Curr Cardiol Rep.  2002;4:141 -148 
ABLATE Post -Appro val Study  
AtriCure Inc. 
Page 39 of 46  CONFIDENTIAL  
Rev. M   
  
 
Appendix A:   Adverse Event Definitions  
 
Acute Coronary Syndrome (ACS): Any constellation of clinical signs or symptoms suggestive of AMI 
(acute myocardial ischemia) or UA (unstable angina). This syndrome includes patients with AMI, STEMI 
(ST-Segment Elevation Myocardial Infarction), NSTEMI (non -ST-elevation myocardial infarction), 
enzyme -diagnosed MI, biomarker -diagnosed MI, late ECG -diagnosed MI, and UA. This term is useful to 
generically refer to patients who ultimately prove to have 1 of these diag noses to describe management 
alternatives at a time before the diagnosis is ultimately confirmed.  
 
Acute respiratory distress syndrome (ARDS): A failure of the respiratory system characterized by fluid 
accumulation within the lung that causes the lung to s tiffen. This condition must be confirmed by 
radiological evidence, or lung biopsy, or the need for prolonged positive pressure ventilation.  
Air Embolism: An inadvertent introduction of air or gas to the vasculature which requires medical 
treatment.  
Allergi c Reaction: An allergic reaction characterized by rash, nausea, vomiting, upper respiratory 
congestion, urticaria, shortness -of-breath, vasovagal reaction, or general collapse (anaphylaxis).  
Anemia : Decrease from baseline in red blood cells, hemoglobin, or  total blood volume that is associated 
with hemodynamic changes or requires transfusion, or a drop in hematocrit to <21 or Hgb < 7. 5%. Any 
documented anemia event requiring ≥ 3 units PRBCs will be considered an SAE.  
 
Angina: Chest pain or discomfort due t o myocardial ischemia. Typical angina is uncomfortable pressure, 
fullness, squeezing or pain in the center of the chest. The discomfort also may be felt in the neck, jaw, 
shoulder, back or arm. Angina should be confirmed by evidence of coronary artery bloc kage such as 
electrocardiographic changes, positive imaging study (radioisotope scanning), coronary angiography or 
cardiac MRI.  
 
Arrhythmia (other than AFIB)  
 
• Bradycardia:  
• Significant Bradycardia is symptomatic bradycardia (with heart rate less than 60 and  symptoms 
attributed to the slow rate) or extreme bradycardia (persistent rates less than 40  bpm).  
• Supraventricular tachycardia (SVT) : Supraventricular rhythm > 100 bpm for > 30 seconds 
Ventricular tachycardia (VT): A regular heart rhythm originating from the ventricle > 120 bpm 
and clinically significant. Sustained VT is > 30 seconds or requires  intervention.  
• Ventricular fibrillation (VF): . An extremely rapid polymorphic ventricular rhythm with essentially 
no cardiac  output.  
 
Arterial embolism: Angiographi c evidence of embolic occlusion in any vascular distribution.  
 
Atelectasis (post surgical): Is a collapse of lung tissue affecting part or all of one lung; the alveoli are 
deflated. This is not considered to be an AE unless treatment other than Chest PT is  required or it 
prolongs hospitalization.  
ABLATE Post -Appro val Study  
AtriCure Inc. 
Page 40 of 46  CONFIDENTIAL  
Rev. M   
  
 
Atrial Fibrillation: A heart rhythm disorder in which the upper chambers of the heart (the atria) contract 
very rapidly in a disorganized manner without effective atrial contraction. AF is characterized by the 
presence of this chaotic uncoordinated electric activity from the atria to the AV node and is associated 
with irregular ventricular response.  The atrial rate can be between 300 to 600 beats per minute.  
 
Atrial Tear/Perforation/Rupture / Bruise: Any evidence of a tear or damage to one of the atria.  
 
Atrial thrombus: Thrombus formation or detection within the atrium.  
 
Atypical Chest Pain: Located under the sternum, left chest, abdomen, back, or arm and is fleeting or 
sharp. It is unrelate d to exercise, not relieved by rest or the administration of nitroglycerin.  
Bacteremia: Presence of viable bacteria in the circulating blood. May be associated with clinical 
signs/symptoms such as fever but not hemodynamic compromise. Must be confirmed by having one 
positive blood culture and no subsequent negative cultures.  
 
Bleeding complications:  
 
Bleeding:  
 
Major bleeding  Is defines as  3 units of blood transfused in a 24 period  
Minor Bleeding  Is  defined as < 3 units of blood transfused within a 24 hour period  
 
Procedural Bleeding: Bleeding occurring during the procedure requiring 3 or more units of blood 
transfused.  
Major Bleeding: Any bleeding which results in a drop in hematocrit from pre -procedure level which is 
associated with hemodynamic compro mise or which results in a hematocrit of ≤ 25% or blood loss  that 
requires transfusion of 3 or more units of  blood.  
 
Coagulopathy: Documented inappropriate coagulation, which leads to the consumption of clotting 
factors, resulting in the failure of the clo tting mechanism at the site of bleeding.  
 
Disseminated intravascular coagulation (DIC): Also known as consumptive coagulopathy , which leads 
to the activation of coagulation (blood clotting) mechanisms. This leads to the formation of small blood 
clots insid e the blood vessels throughout the body.  
Hematoma: Development of a collection of blood > 5 cm’s under the skin requiring transfusion or 
surgical intervention to resolve.  
Intracranial Hemorrhage: Includes all bleeding within the cranium either subarachnoid, intra - 
parenchymal, or intracerebral.  
ABLATE Post -Appro val Study  
AtriCure Inc. 
Page 41 of 46  CONFIDENTIAL  
Rev. M   
  
 
GI Bleed: Detection of frank blood or hemoglobin in the stool which requires medical intervention 
including but not limited to transfusion, medication, surgical intervention, prolongation of hospital stay, 
or re -hospitalization . 
Cardiac Arrest: Cardiac arrest is the sudden, abrupt loss of heart function. Often related to malignant 
arrhythmia.  Results in sudden death unless acutely successfully resuscitated . 
Cardiac Tamponade: The compression of the heart caused by blood or fluid accumulation in the space 
between the myocardium and the pericardium. Cardiac tamponade (also referred to as pericardial 
tamponade or tamponade) is associated with a hemodynamic profile characterized by  equalization of 
right and left heart diastolic pressures and/or pulsus paradoxicus (a > 15cm drop in blood pressure 
during inspiration).  
 
Coronary Artery Injury:  Damage to the artery caused during surgery requiring repair.  
 
Cardiac Valve Injury: Damage t o any cardiac valve resulting from the index surgical procedure.  
 
Cardiogenic Shock: Patient presents with SBP < 80 mm Hg for more than 30 minutes unresponsive to 
fluids and / or requiring intravenous pressor agent or an intraortic balloon pump (IABP).  
 
Congestive Heart Failure (CHF): A clinical syndrome caused by heart disease, characterized by 
breathlessness and abnormal sodium and water retention, and resulting in edema. This term is used 
when there is congestion of pulmonary or systemic vascular beds.  
 
Death: All cause mortality. Death is not an adverse event, it is an outcome. The Adverse Event is what 
caused the death. Death (within the first 30 days postoperative or >30 days if procedure related).  
 
Sudden Death: Cardiac arrest which is unexpected an d occurs within minutes of the onset of symptoms.  
 
Damage to intra -thoracic structures other than the heart (e.g., lungs, trachea, esophagus, 
aorta/arteries, vena cava/veins, etc.): Any evidence of puncture/dissection/perforation or damage to 
any non -cardi ac structure within the thoracic cavity requiring intervention.  
Deep Vein Thrombosis (DVT): Unilateral lower extremity swelling, redness, pain with confirmation by 
Doppler tests of obstructed venous flow in that extremity. DVT occurring within 30 days of t he surgical 
procedure shall be considered procedure related.  
Diaphragmatic paralysis: May be unilateral or bilateral. May be caused by injury to the phrenic nerve as 
a result of trauma  to the thoracic  cage.  
Drug Reaction: Adverse event related to a drug reaction to the anesthesia or intercostal blocks (pain 
medications) used during the su rgical procedure.  
ABLATE Post -Appro val Study  
AtriCure Inc. 
Page 42 of 46  CONFIDENTIAL  
Rev. M   
  
 
Endocarditis: An infection associated with classic signs of endocarditis (positive blood cultures, fever, 
red blood cell casts in urine, splinter hemorrhages in finger nails, roof of mouth, lesions on retina, etc) 
associat ed with a vegetation inside the atrium or on a valve which may be confirmed on echo 
cardiography.  
Esophageal Fistula: Abnormal passage communicating with the esophagus (for the purposes of this 
protocol - likely resulting from an esophageal rupture).  
Esophageal rupture: Any evidence of puncture/dissection/perforation or damage to the esophagus.  
 
Fever: A temperature > 101°F / 38.5°C  not related to a culture positive infection.  
 
General Discomfort: Physical or psychosocial signs or symptoms commonly associated with 
hospitalization that are investigated and determined to require minor (i.e. aspirin, non -narcotic 
medication) or no, treatment.  
 
Headache: Aching or pain that occurs in one or more areas of the head, face, mouth, or neck. Headache 
can be ch ronic, recurrent, or occasional. The pain can be mild or severe enough to disrupt daily 
activities.  
 
Hemoptysis: A cough that produces bloody sputum.  
 
Hemolysis: The breakdown of red blood cells.  
 
Heparin -Induced Thrombocytopenia (HIT): A 50% or greater fa ll in the platelet count from the 
postoperative peak1 which may be confirmed with + antiplatelet antibodies.  
 
Hepatic Failure: A clinical condition that results from severe and extensive damage of liver cells leading 
to failure of the liver to function nor mally and can induce mental confusion of various degrees. Liver 
failure is described as the combination of hyperbilirubinemia (Total Bilirubin >2), Coagulopathy with INR 
level greater than the upper limits of normal (in the absence of Coumadin treatment) a nd 
Hypoalbuminemia, with an albumin <3.  
 
Hyperglycemia: The use of insulin in the post op period does not constitute hyperglycemia if during the 
same hospitalization. An Elevated blood sugar of less than 250 during the first 48 hours post op does not 
constitute hyperglycemia.  
 
Hypertension: Systolic BP > 140 mmHg, or diastolic > 90 mmHg requiring specific medical therapy.  
 
 
 
 
1 Warkentin TE, et al. An improved definition of immune heparin -induced thrombocytopenia in postoperative 
orthopedic patients.  Arch Intern Med. 2003 Nov 10;163(20):2518 -24. 
ABLATE Post -Appro val Study  
AtriCure Inc. 
Page 43 of 46  CONFIDENTIAL  
Rev. M   
  
 
 
Hypotension: Low blood pressure requiring medical intervention or treatment with medication.  
 
Infection: The following are the categories for infections:  
 
• Deep Sternal: Involving muscle, bone,  and/or  mediastinum.  
• Thoracotomy Site: Involving a thoracotomy or parasternal  site.  
• Lung: Involving airways associated with intubation or other respiratory  causes.  
• Leg: Involving a leg vein harvest  site. 
• Chest tube: Involving the chest tube insertion  site 
• UTI: Involving the urinary  tract.  
• Pacemaker site: Involving the incision line created for pacemaker  placement  
• Or Systemic Infection: Bloodstream infection caused by  bacteria.  
 
Each type of infection should be classified as either Major or Minor as outlined  
below:  
• Infection Major: Life threatening or requiring surgical  intervention.  
• Infection Minor: Temperature > 101°F / 38.5°C or higher and a positive culture (e.g., tissue, 
urine, etc.). Easily eradicated requiring a brief course of  antibiotics.  
 
 
Leukopeni a:  Leukopenia is defined as leukocyte count of <3.5 x109/liter for more than 3 days.  
 
Limb ischemia: Limb ischemia is manifested by pain in an extremity at rest, associated with non -healing 
wounds and gangrene. Limb ischemia should be confirmed by diagnos tic imaging studies.  
Medication Reaction: An unwanted or harmful side effect experienced following the administration of a 
drug or combination of drugs and is suspected to be related to the drug.  
 
Multi -organ failure: Failure of more than one organ due to shock or sepsis. This requires volume and 
inotropic support and has a high incidence of death.  
Myocardial infarction: Myocardial damage detected either by electrocardiographic changes including ST 
segment elevation, laboratory evaluation (e.g., elevated le vels of serum CPK -MB, troponin -I) or cardiac 
imaging studies (echocardiographic images showing reduction in ejection fraction from the pre - 
operative level).  
 
Nausea: The unsettling feeling in the stomach that accompanies the urge to vomit.  
 
Neutropenia:  Neutropenia is defined as ANC <1000 per mm3 for more than 3 days.  
 
Ogilvie Syndrome/Acute Colonic Pseudo -Obstruction (ACPO): Clinical disorder with the signs, symptoms 
and radiographic appearance of an acute large bowel dilatation with no evidence of dista l colonic 
obstruction.  
ABLATE Post -Appro val Study  
AtriCure Inc. 
Page 44 of 46  CONFIDENTIAL  
Rev. M   
  
 
Pain: An unpleasant sensation occurring in varying degrees of severity as a consequence of injury, disease, 
or emotional disorder.  
Pain (Persistent Chest Pain): Post discharge surgical incisional pain, not angina.  
 
Pericardial Tamponade:  See Cardiac Tamponade.  
 
Pericarditis: Infection of the pericardium which may or may not require re -operation.  
 
Peripheral Edema: The swelling  of tissues , usually in the lower limbs , due the accumulation of fluids.  
 
Pleural Effusion: Accumulation of fluid in the pleural spac e evidenced by x -ray, echocardiography, CT 
Scan or other appropriate diagnostic technique and which requires drainage.  
Pneumothorax: Air in the thoracic cavity associated with partial collapse of a lung with chest tube 
drainage.  
 
Pneumonia: An inflammation  of the lungs caused by an infection. This condition must be confirmed by 
radiological evidence, positive sputum culture, or significant improvement of the condition following 
antibiotic treatment.  
Pulmonary edema: Pulmonary edema is present if there is fl uid accumulation in the lungs caused by 
backpressure in the lung veins. This condition must be confirmed by radiological evidence or lung water 
measurements.  
Pulmonary embolism: an obstruction of a blood vessel in the lungs, usually due to a blood clot, wh ich 
blocks a pulmonary artery.  
Pulmonary hypertension: Patient has mean pulmonary artery pressure that is greater than 25 mmHg at 
rest and/or greater than 30 mmHg during exercise as measured by right heart catheterization.  
Pulmonary vein stenosis: Defined 70% stenosis of one pulmonary vein or 50% stenosis of more than 
one vessel. PV stenosis is manifest as dyspnea at rest, may be associated with hemoptysis and must be 
confirmed by imaging studies of the pulmonary veins (using CT or MRI).  
Pulmonary vein stenosis, suspected: Any patients exhibiting mild or suspected pulmonary vein stenosis 
(defined as >40% stenosis of one vein or >30% in more than one vein) shall undergo additional imaging 
studies at 12 months or as needed.  
Pseudo -aneurysm: Disruption of t he arterial wall characterized by an outpouching or pocket with 
swirling, flowing blood outside of the confines of the arterial lumen.  
Respiratory failure: Need for mechanical ventilation beyond 48 hours of completion of surgical 
procedure(s), or the need for re -intubation and ventilator support occurring at any time within 30 days 
of the surgical procedure, outside the setting of an additional operation.  
ABLATE Post -Appro val Study  
AtriCure Inc. 
Page 45 of 46  CONFIDENTIAL  
Rev. M   
  
Renal failure: a.) Increase of > 2.0 mg/dl in serum creatinine from any previous value o r, b.)  50% 
increase over baseline to a level that is  the upper limit of normal which may require dialysis. .  
Reoperation: A repeat operation for the same condition in the same patient or to resolve an adverse 
event resulting from the initial operation.  Reoperation is not an adverse event – it is an outcome – the 
reason for reoperation is the adverse event.  
Restrictive (constrictive) pericarditis: A chronic  form of pericarditis  in which the pericardium is rigid, 
thickened, scarred, and less elastic than normal. The pericardium cannot stretch as the heart beats, 
which prevents the chambers of the heart from filling.  
 
Retroperito neal bleeding: Documented collection of blood in the retroperitoneum or by CT/MR.  
 
Sepsis: Positive blood cultures associated with cardiovascular collapse and signs and symptoms of 
multiorgan failure.  
Septicemia : Positive blood cultures.  
 
Seizures: Sudden,  uncontrolled muscle spasms with or without loss of consciousness resulting from 
brain electrical activity.  
Sick sinus syndrome: Also called sinus node dysfunction , is a group of abnormal heart rhythms 
(arrhythmia) presumably caused by a malfunction of the  sinus node, the heart's primary pacemaker, 
often resulting in the combination of sinus bradycardia alternating with rapid supraventricular rhythms 
such as afib with rapid ventricular response, as tachycardia -bradycardia syndrome  
 
Stroke (permanent disabil ity): A loss of brain function that occurs when the blood supply to any part of 
the brain is interrupted, resulting in tissue death or that which occurs with cerebral hemorrhage with 
clinical sequelae lasting more than 24 hours. Clinical signs/symptoms of neurological deficit as 
determined by standard comprehensive neurological examination, neurological imaging (CT scan or 
MRI) or autopsy.  
May be further categorized as:  
 
• Ischemic Stroke: Neurologic deficit attributed to thromboembolic  event.  
• Hemorrhagic Stroke: Neurologic deficit meeting the study definition for Stroke that is attributed 
to bleeding into brain tissue, epidural, subdural, or subarachnoid space; or a combination of 
these  sites.  
 
Thrombocytopenia : A persistent decrease in the num ber of blood platelets to subnormal levels.  
 
Thromboembolism: Formation of a thrombus ( masses composed of insoluble fibrin, deposited platelets, 
accumulating WBCs, and entrapped RBCs ) that obstructs vascular blood flow locally and detaches and 
embolizes to  occlude blood flow downstream.  Diagnostic confirmation should be made with 
angiography or ultrasound.  
ABLATE Post -Appro val Study  
AtriCure Inc. 
Page 46 of 46  CONFIDENTIAL  
Rev. M   
  
 
 
Thrombus: Blood clot that obstructs a blood vessel.  
 
Transient Ischemic Attack (TIA): A neurological deficit lasting less than 24 hours  and if an imaging study 
is performed showing no evidence of infarction.  
Unstable Angina: Angina which increases in frequency, intensity, or duration, which occurs at rest, or 
which is new in onset. Unstable angina is a syndrome that is intermediate betwee n stable angina and 
myocardial infarction: it is characterized by an accelerating or "crescendo" pattern of chest pain that 
lasts longer than stable angina, occurs at rest or with less exertion than stable angina, or is less 
responsive to medication. Unsta ble angina and myocardial infarction are considered acute coronary 
syndromes.  
Vasovagal Reaction: Reflex stimulation of the vagus nerve causing slowing of the heartbeat, decreased 
blood pressure, lightheadedness or syncope, etc. and requires treatment cons isting of any of the 
following: (a) > 1 liter of IV fluids; (b) postural changes; (c) pacing intervention; or (d) administration of 
atropine.  
 
Ventricular tear / perforation / bruise /rupture: Any evidence of puncture/dissection/ perforation or 
damage to t he ventricle. The AtriCure Bipolar System is not intended to be used in the ventricle. Care 
should be taken during introduction of the device on the left side of the heart so that the clamps and 
shaft of the device do not come in contact with the ventricle  and cause disruption of the ventricular 
tissue.  
 
Wound dehiscence/delayed wound healing:  Not associated with infection.  